Using these guidelines
The Bone Marrow and Peripheral Blood Stem Cell Donor Selection Guidelines (BM-DSG) apply to unrelated donors giving bone marrow and peripheral blood stem cells for therapeutic use.
The BM-DSG forms a constituent part of Chapter 22 of the Guidelines for the Blood Transfusion and Tissue Transplantation Services in the UK.
JPAC is responsible for these guidelines and receives professional advice from its specialist Standing Advisory Committees and other relevant expert groups. The BM-DSG is primarily reviewed and updated by the Standing Advisory Committee on Cellular Therapy Products (SACCTP). It is reviewed regularly to ensure that donations are of the highest quality and of sufficient quantity to meet the needs of recipients.
Comments about the content of the BM-DSG, including notification of errors, omissions and suggestions for improvements, should be sent to JPACOffice@nhsbt.nhs.uk.
General principles
Important
These guidelines are for healthcare professionals who are trained in their use.
JPAC cannot answer individual donor queries or provide personal medical advice. Help with such matters may be available through a local blood and tissue service.
Donations must not be accepted from donors who exhibit health risks that are not listed in these guidelines without referral to, and acceptance by, a Designated Clinical Support Officer.
Donors are selected firstly to ensure that they do not come to harm from giving their donation and secondly to ensure that their donation is unlikely to harm any recipient.
The ultimate responsibility for the selection of donors rests with the Medical Director of each UK Blood and Tissue Service (UKBTS).
The immediate responsibility is with the Qualified Healthcare Professional who must ensure that the donor fulfills the respective selection criteria. When it is not clear from these guidelines if an individual donor is suitable, no donation should be taken without discussion with a Designated Clinical Support Officer.
It is recognised that a particular donation of bone marrow or peripheral blood stem cells may be potentially and uniquely life saving. It is important that when a Designated Clinical Support Officer makes a concession outside of these guidelines, that this is discussed with the medical team of the recipient and the reasoning for the concession is documented.
The prospective donor must be evaluated for their eligibility to donate by a Qualified Healthcare Professional who has undergone appropriate training to use these guidelines to select or defer a donor. They must verify their assessment by signing the donation record.
Special note must be taken of the content of the Tissues safety entry.
It is the responsibility of the Qualified Healthcare Professional to ensure that the donor clearly understands the nature of the donation process, the health check and other medical information presented to them. Donors are asked about confidential aspects of their medical history, hence great care must be taken over privacy and confidentiality.
Where there is separate guidance for Bone Marrow and for Peripheral Blood Stem Cell donors, this is made clear. When there is a recognised risk to either the donor or the recipient, the guidelines must be followed.
Use of the A to Z index
Any medical condition or possible contraindication to donation, elicited at any point during the donation process, must be managed as indicated by its respective guideline entry. A complete list of available entries can be found in the A to Z index. Any collected material which, as a result, is unsuitable for clinical use must be clearly labelled as unfit for use.
If late information is provided by the donor, or through any other source, that the donation is medically unfit, this must be recorded and reported to the Designated Clinical Support Officer.
Any new health risks identified during the donor selection process should be notified to SACCTP so that they can be considered for incorporation into future revisions of the BM-DSG.
Guideline terminology
Please note, not all of the terms given below appear on every guideline entry.
Medication
The underlying illness suffered by a donor, rather than the properties of any drug they are taking, is the usual reason for an ineligiblity to donate.
In general, traces of drugs in donations are harmless to their recipients. However, donors treated with certain drugs are deferred for periods associated with the pharmacokinetic properties of the drug. Examples are drugs used to treat acne, psoriasis, and some prostate problems. All such drugs have their own entry.
Version control
The BM-DSG is under the continuing review of SACCTP and the Standing Advisory Committee on Transfusion Transmitted Infection (SACTTI) to ensure that they are accurate and up to date.
All changes are the responsibility of the Professional Director of JPAC and have the approval of the Executive Working Group (EWG) and the JPAC Board.
The Quality Manager of each UKBTS will be notified of upcoming changes by electronic distribution of a Change Notification.
The Quality Manager is responsible for effecting changes to locally held copies of the guidelines, or to information adapted from the guidelines for use within their respective service. An effective version control and change procedure must be in place to ensure only current versions of the guidelines are in use and that all authorised copies, electronic and paper, are traceable.
Live version of the guidelines (this website)
The website will always display the current version of each guideline entry, as shown in the A to Z index, and each entry will shown the date of its most recent update. Changes will be published on the website on the effective date given in the relevant Change Notification.
Offline version of the guidelines (source files)
A source file is a downloadable copy of the guidelines. A source file containing the current version of the guidelines is always available on the Source files page.
In addition, whenever a Change Notification is distributed to indicate upcoming changes, an updated source file incorporating those changes will be made available. This will supersede the current source file on the effective date of the Change Notification and any previous source files will be removed.
Last updated in BM-DSG Edition 203 Release 59 (1 May 2026)